{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:55:37Z","timestamp":1767178537723,"version":"build-2238731810"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"OEGEO"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0189641","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T16:04:27Z","timestamp":1513353867000},"page":"e0189641","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-0987","authenticated-orcid":true,"given":"Daphne","family":"Gschwantler-Kaulich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid","family":"Weingartshofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rappaport-F\u00fcrhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zeilinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Pils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Muhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena I.","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Therese","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3322\/caac.21392","article-title":"Cancer Screening in the United States, 2017: A review of current american cancer society guidelines and current issues in cancer screening","volume":"67","author":"RA Smith","year":"2017","journal-title":"Ca Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"MC King","year":"2003","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00508-015-0880-x","article-title":"Clinical Practice Guidline for the prevention and early detection of breast and ovarian caner in women from HBOC (hereditary breast and ovarian cancer) families","volume":"127","author":"CF Singer","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2014.56.8626","article-title":"Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density","volume":"33","author":"CC Riedl","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"IJ Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0090-8258(03)00051-9","article-title":"Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation","volume":"89","author":"JL Wilder","year":"2003","journal-title":"Gynaecol Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.2003.02.054","article-title":"Ultrasound screening for the early detection of ovarian cancer","volume":"21","author":"PD DePriest","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of mulitmodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK\u2013Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"U Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"SS Buys","year":"2011","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2015.09.018","article-title":"Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review","volume":"139","author":"MG Patrono","year":"2015","journal-title":"Gynecol Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-010-0799-x","article-title":"Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1\/2 mutation carriers","volume":"124","author":"SM Domchek","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study","volume":"23","author":"A Eisen","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"TR Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"7","author":"SM Domchek","year":"2006","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/2013.jamainternmed.962","article-title":"Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing","volume":"173","author":"GN Mannis","year":"2013","journal-title":"JAMA Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9792756","article-title":"HE4 serum levels in patients with BRCA1 gene mutation undergoing prophylactic surgery as well as in other benign and malignant gynecological diseases","volume":"2017","author":"A Chudecka-G\u0142az","year":"2017","journal-title":"Dis Markers"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1055-9965.EPI-13-1361","article-title":"Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women","volume":"23","author":"BY Karlan","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/1078-0432.CCR-07-1569","article-title":"Diagnostic Markers for Early Detection of Ovarian Cancer","volume":"14","author":"I Visintin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2407-13-178","article-title":"A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer- a study of the OVCAD consortium","volume":"13","author":"D Pils","year":"2013","journal-title":"BMC Cancer"},{"key":"ref20","first-page":"7667","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"G Mor","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref21","year":"2008"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1093\/bioinformatics\/bti623","article-title":"ROCR: visualizing classifier performance in R","volume":"21","author":"T Sing","year":"2005","journal-title":"Bioinformatics"},{"key":"ref23","first-page":"1","article-title":"OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests","volume":"61","author":"Maria Xose Rodriguez-Alvarez Monica Lopez-Raton","year":"2014","journal-title":"Journal of Statistical Software"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/1055-9965.EPI-15-1299","article-title":"Validation of novel biomarker panel for the detection of ovarian cancer","volume":"25","author":"F Leung","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13048-017-0315-6","article-title":"Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort","volume":"10","author":"RT Fortner","year":"2017","journal-title":"J Ovarian Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/IGC.0000000000000804","article-title":"Diagnostic performance of Risk of Ovarian Cancer Algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis","volume":"26","author":"F Dayyani","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/diagnostics7010014","article-title":"A perspective on ovarian cancer biomarkers: past, present and yet-to-come","volume":"7","author":"FR Ueland","year":"2017","journal-title":"Diagnostics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s13402-016-0309-1","article-title":"Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer","volume":"40","author":"K El Bairi","year":"2017","journal-title":"Cell Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cca.2015.03.047","article-title":"HE4 in the differential diagnosis of ovarian masses","volume":"446","author":"T Granato","year":"2015","journal-title":"Clin Chim Acta"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/IGC.0000000000000192","article-title":"Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis; a systematic review and meta-analysis","volume":"24","author":"AC Macedo","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.7314\/APJCP.2012.13.11.5427","article-title":"Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis","volume":"13","author":"JY Lin","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/IGC.0b013e318263efa2","article-title":"Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis","volume":"22","author":"L Wu","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian cancer in patients with a pelvic mass","volume":"108","author":"RG Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"RG Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"S Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"G Scaletta","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?","volume":"128","author":"R Angioli","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"F Plotti","year":"2012","journal-title":"Tumour Biol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","article-title":"Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature","volume":"34","author":"S Capriglione","year":"2017","journal-title":"Med Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13048-016-0254-7","article-title":"Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses","volume":"9","author":"KM Terlikowska","year":"2016","journal-title":"J Ovarian Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"82.e1","DOI":"10.1016\/j.ajog.2016.03.003","article-title":"Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses","volume":"215","author":"R Coleman","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/ijms18010123","article-title":"Diagnostic value of serum angiogenesis markers in ovarian cancer using Multiplex Immunoassay","volume":"18","author":"A Horala","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"26587","DOI":"10.1074\/jbc.M604403200","article-title":"BRCA1 suppresses osteopontin-mediated breast cancer","volume":"281","author":"MK El-Tanani","year":"2006","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5468\/ogs.2016.59.4.279","article-title":"Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer","volume":"59","author":"JH Jin","year":"2016","journal-title":"Obstet Gynecol Sci"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10552-013-0156-6","article-title":"Circulating prolactin levels and risk of epithelial ovarian cancer","volume":"24","author":"TV Clendenen","year":"2013","journal-title":"Cancer Causes Control"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2011.05.039","article-title":"Comparison of cancidate serologic markers for type I and type II ovarian cancer","volume":"122","author":"D Lu","year":"2011","journal-title":"Gynecol Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1701-2163(16)35273-2","article-title":"Combination of serum biomarkers to differentiate malignant from benign ovarian tumors","volume":"34","author":"G He","year":"2012","journal-title":"J Obstet Gynaecol Can"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-16-1391","article-title":"EPIC early detection of ovarian cancer","volume":"22","author":"SJ Skates","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","article-title":"A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort","volume":"22","author":"KL Terry","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancers: Updated Guidelines From the European Group on Tumor Markers","volume":"26","author":"G S\u00f6l\u00e9tormos","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"ref51","article-title":"Early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm with frequent CA125 testing in women at increased familial risk- combined results from two screening trials","author":"SJ Skates","year":"2017","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0196142","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0189641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T14:45:28Z","timestamp":1540219528000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0189641"}},"subtitle":[],"editor":[{"given":"Amanda Ewart","family":"Toland","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0189641","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}